
Phase 2 ARDA Findings Support Development of Empasiprubart in Multifocal Motor Neuropathy
Newly presented data from the phase 2 ARDA study (NCT05225675) showed that treatment with empasiprubart (Argenx), a C2-binding agent, was safe and reduced the need for intravenous immunoglobulin (IVIg) retreatment in patients with multifocal motor …